Syngen Biotech Co.,Ltd. (TPEX:8279)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
116.50
-2.50 (-2.10%)
Mar 3, 2026, 11:33 AM CST
-10.04%
Market Cap 3.23B
Revenue (ttm) 2.14B
Net Income (ttm) 271.59M
Shares Out 27.10M
EPS (ttm) 10.01
PE Ratio 11.89
Forward PE n/a
Dividend 5.00 (4.17%)
Ex-Dividend Date Jun 26, 2025
Volume 99,429
Average Volume 84,806
Open 118.00
Previous Close 119.00
Day's Range 115.50 - 118.50
52-Week Range 100.00 - 148.00
Beta 0.21
RSI 38.72
Earnings Date Mar 4, 2026

About Syngen Biotech

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredient... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 247
Stock Exchange Taipei Exchange
Ticker Symbol 8279
Full Company Profile

Financial Performance

In 2025, Syngen Biotech's revenue was 2.14 billion, an increase of 6.10% compared to the previous year's 2.01 billion. Earnings were 271.59 million, an increase of 13.07%.

Financial Statements

News

There is no news available yet.